Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.
- ET / 2:30 p.m. PT
SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates. - Based on these results, the Company plans to discuss a tumor agnostic Accelerated Approval approach with FDA by year-end 2023.
- Net reduction in cash, cash equivalents and short-term investments for the second quarter of 2023 was $122.9 million.
- ET / 2:30 p.m. PT during which company executives will review financial information for the second quarter and provide corporate updates.